跳至主要内容
临床试验/EUCTR2012-003589-42-DE
EUCTR2012-003589-42-DE
进行中(未招募)
不适用

Observational (non-interventional), follow-up trial assessing long-term local tolerability and efficacy (recurrence rate) of resiquimod gel in patients treated for actinic keratosis.

Spirig Pharma AG0 个研究点目标入组 80 人2012年12月19日

概览

阶段
不适用
干预措施
未指定
疾病 / 适应症
Actinic Keratosis
发起方
Spirig Pharma AG
入组人数
80
状态
进行中(未招募)
最后更新
11年前

概览

简要总结

暂无简介。

注册库
who.int
开始日期
2012年12月19日
结束日期
待定
最后更新
11年前
研究类型
Interventional clinical trial of medicinal product
性别
All

研究者

入排标准

入选标准

  • Signed informed consent.
  • Participation in the previous clinical trial SP848\-AK\-1101\.
  • Patient with complete clinical clearance (i.e. no previously existing AK\-lesion present) at the end of the trial SP848\-AK\-1101 or Non\-Responder who withdrew from the trial prematurely.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range 30
  • F.1\.3 Elderly (\>\=65 years) yes
  • F.1\.3\.1 Number of subjects for this age range 50

排除标准

  • Evidence of unstable or uncontrolled clinically significant medical conditions as determined by the investigator (e.g., cardiovascular, immunological, hematologic, hepatic, neurologic, renal, endocrine, collagen\-vascular, infectious, gastrointestinal abnormalities or diseases).
  • Evidence of systemic cancer.
  • Dermatological disease or condition in the former treatment or surrounding area that might
  • impair trial assessments (e.g., rosacea, atopic dermatitis, eczema) as assessed by the investigator.

结局指标

主要结局

未指定

相似试验